Biotech leaders seek more funding to stay competitive
By: BRADLEY J. FIKES - Staff Writer | ∞
SAN DIEGO ---- Decreased federal spending on health care research is crimping the nation's biotechnology industry and prompting U.S.-trained, foreign-born scientists to seek better opportunities at home, speakers at a biotechnology conference warned Tuesday.
The Calbio conference in downtown San Diego was sponsored by Biocom, the region's life science industry group.
Speakers lamented the slowdown in funding from the National Institutes of Health, the single largest funder of biomedical research in the country.
After doubling from fiscal year 1999 to $27 billion in 2003, the NIH has slipped, said speakers during a panel discussion moderated by Greg Lucier, chief executive of Carlsbad's Invitrogen Corp. The fiscal year 2006 budget was $28.8 billion, a decrease when inflation is taken into account.
The result, the panel said, is that promising young researchers are being shut out of funding. Some foreign-born researchers are beginning to return to their native countries, which are stepping up biotech spending.
That trend would threaten San Diego's large biomedical industry, which is fueled by discoveries made by biotech scientists. Researchers at UC San Diego, for example, pull in hundreds of millions of dollars in NIH funding annually.
Funding the NIH, Lucier said, is a "long-term investment" in helping cure major diseases. "The cumulative annual cost to our country ... of stroke, cancer, diabetes and Alzheimer's, will be over $750 billion this year alone," he said. "It seems the price the country is paying, relative to the investment, is somewhat disproportionate."
Universities that had expanded buildings and lab spaces to accommodate expected increases in research funding now find themselves in the lurch, said Jon Retzlaff, director of legislative relations for the Federation of American Societies for Experimental Biology.
"The cost of equipment, the cost of salaries and individuals goes up each year, and NIH is not providing any of that additional funds," Retzlaff said.
Newly minted postdoctoral researchers, who rely on NIH grants to get off the ground, find it tougher to compete, said Janet Lynch Lambert, vice president of governmental relations for Invitrogen. Many researchers here from foreign countries find the scientific climate less inviting than before.
"That's happening here in the U.S., when for the first time, you're starting to see in many countries much more attractive opportunities for folks to return home. We're losing some of the best and brightest who are being lured back with offers in their home country," Lambert said.
The cure, the speakers said, is for biomedical executives and researchers to lobby congressmembers about the importance of increasing funding.
-- Contact staff writer Bradley J. Fikes at (760) 739-6641 or bfikes@nctimes.com.
More Stories
- Biotech leaders seek more funding to stay competitive
- Bernanke calls for stronger regulation of Fannie Mae and Freddie Mac
- Topps agrees to $385.4M takeover led by ex-Disney boss Eisner, but board member vows fight
- Factory orders plunge by largest amount in 6.5 years
- Wall Street rebounds as stocks rise overseas
Advertisement
Unrealistic expectations wrote on Mar 7, 2007 6:14 PM:It's very unrealistic to anticipate that the NIH budget can continue to double every four years. I'd like to see an article like this that proposes solutions to the problem other than a constantly growing budget. We have several scientists in our family, so I'm familiar with today's harsh climate. How about more collaborations, sharing of equipment, and retiring some of the older, perhaps not so productive, staff? I think that it's refreshing that scientists have opportunities in other countries; in the long run it's better for all of us.
Jim wrote on Mar 16, 2007 9:04 AM:Ivgn's sales doubled from 199 - 2003. That was the result of purchasing other biotech firms (most notably Life Technologies). Invitrogen has not performed well financially outside of the "mergers". They tried to make a megacorp by piecing together separate copmanies. The glue never took and now Ivgn is paying the price.
First name only. Comments including last names, contact addresses, e-mail addresses or phone numbers will be deleted. Attempts to misrepresent your identity or impersonate any person will not be approved. All comments are screened before they appear online, so please keep them brief. Comments reflect the views of those commenting and not necessarily those of the North County Times or its staff writers. Click here to view additional comment policies.
Today's Stories
Advertisement


